130 related articles for article (PubMed ID: 7524792)
1. A multicentre in vitro evaluation of piperacillin/tazobactam in Germany.
Grimm H
Eur J Surg Suppl; 1994; (573):25-9. PubMed ID: 7524792
[TBL] [Abstract][Full Text] [Related]
2. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
Sader HS; Tosin I; Sejas L; Miranda E
Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
[TBL] [Abstract][Full Text] [Related]
3. Multicentre survey of the comparative in-vitro activity of piperacillin/tazobactam against bacteria from hospitalized patients in the British Isles.
Chen HY; Bonfiglio G; Allen M; Piper D; Edwardson T; McVey D; Livermore DM
J Antimicrob Chemother; 1993 Aug; 32(2):247-66. PubMed ID: 8226427
[TBL] [Abstract][Full Text] [Related]
4. In-vitro activity of piperacillin and tazobactam combination against clinically significant bacteria.
Obi CL; Makandiramba B; Robertson V; Tswana SA; Moyo SR; Nziramasanga P
East Afr Med J; 1998 Mar; 75(3):162-5. PubMed ID: 9640815
[TBL] [Abstract][Full Text] [Related]
5. Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830).
Jones RN; Barry AL
Diagn Microbiol Infect Dis; 1989; 12(6):495-510. PubMed ID: 2560422
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of piperacillin/tazobactam and other broad-spectrum antibiotics against bacteria from hospitalised patients in the British Isles.
Livermore DM; Mushtaq S; James D; Potz N; Walker RA; Charlett A; Warburton F; Johnson AP; Warner M; Henwood CJ
Int J Antimicrob Agents; 2003 Jul; 22(1):14-27. PubMed ID: 12842324
[TBL] [Abstract][Full Text] [Related]
7. Argentinean collaborative multicenter study on the in vitro comparative activity of piperacillin-tazobactam against selected bacterial isolates recovered from hospitalized patients.
Casellas JM; Tomé G; Bantar C; Bertolini P; Blázquez N; Borda N; Couto E; Cudmani N; Guerrera J; Juárez MJ; López T; Littvik A; Méndez E; Notario R; Ponce G; Quinteros M; Salamone F; Sparo M; Sutich E; Vaylet S; Wolff L
Diagn Microbiol Infect Dis; 2003 Nov; 47(3):527-37. PubMed ID: 14596972
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility survey of piperacillin/tazobactam and some beta-lactam comparators in Italy.
Stefani S; Bonfiglio G; Bianchi C; Zollo A; Nicoletti G
Drugs Exp Clin Res; 1998; 24(2):105-13. PubMed ID: 9675551
[TBL] [Abstract][Full Text] [Related]
9. Potency and antimicrobial spectrum update for piperacillin/tazobactam (2000): emphasis on its activity against resistant organism populations and generally untested species causing community-acquired respiratory tract infections.
Johnson DM; Biedenbach DJ; Jones RN
Diagn Microbiol Infect Dis; 2002 May; 43(1):49-60. PubMed ID: 12052629
[TBL] [Abstract][Full Text] [Related]
10. Susceptibility survey of piperacillin alone and in the presence of tazobactam.
Acar JF; Goldstein FW; Kitzis MD
J Antimicrob Chemother; 1993 Jan; 31 Suppl A():23-8. PubMed ID: 8383653
[TBL] [Abstract][Full Text] [Related]
11. In-vitro activity of piperacillin/tazobactam relative to other antibiotics against blood culture isolates.
Cormican M; Corbett-Feeney G; Kelly S; Hughes D; Flynn J; Jones RN
Ir J Med Sci; 1998; 167(3):155-9. PubMed ID: 9780564
[TBL] [Abstract][Full Text] [Related]
12. The activity of piperacillin/tazobactam against clinical isolates collected in 20 UK centres and the design of a disc test for susceptibility testing.
Reeves DS; Holt HA; Bywater MJ; MacGowan AP
J Antimicrob Chemother; 1993 Jul; 32(1):51-61. PubMed ID: 8226417
[TBL] [Abstract][Full Text] [Related]
13. Comparative in-vitro activity of piperacillin and piperacillin plus tazobactam towards beta-lactamase producing clinical isolates.
Stefani S; Castiglia P; Maida A; Muresu E; Mezzatesta ML; Nicoletti G
J Chemother; 1990 Oct; 2(5):295-9. PubMed ID: 1965317
[TBL] [Abstract][Full Text] [Related]
14. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V
J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
[TBL] [Abstract][Full Text] [Related]
15. Comparison of fixed concentration and fixed ratio options for testing susceptibility of gram-negative bacilli to piperacillin and piperacillin/tazobactam.
Pfaller MA; Barry AL; Fuchs PC; Gerlach EH; Hardy DJ; McLaughlin JC
Eur J Clin Microbiol Infect Dis; 1992 Aug; 11(8):728-32. PubMed ID: 1330566
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of piperacillin/tazobactam versus other broad-spectrum antibiotics against nosocomial gram-negative pathogens isolated from burn patients.
Mokaddas E; Rotimi VO; Sanyal SC
J Chemother; 1998 Jun; 10(3):208-14. PubMed ID: 9669645
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial susceptibility of well-characterised multiresistant CTX-M-producing Escherichia coli: failure of automated systems to detect resistance to piperacillin/tazobactam.
Pitout JD; Le P; Church DL; Gregson DB; Laupland KB
Int J Antimicrob Agents; 2008 Oct; 32(4):333-8. PubMed ID: 18701262
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of in vitro susceptibility of hospital bacterial isolates to piperacillin and tazocin (piperacillin/tazobactam].
Birawska I; Fuchs J; Szulakowska E
Med Dosw Mikrobiol; 1998; 50(1-2):41-6. PubMed ID: 9857612
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic/pharmacodynamic modeling to predict in vivo effectiveness of various dosing regimens of piperacillin/tazobactam and piperacillin monotherapy against gram-negative pulmonary isolates from patients managed in intensive care units in 2002.
Frei CR; Burgess DS
Clin Ther; 2008 Dec; 30(12):2335-41. PubMed ID: 19167592
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of ceftriaxone plus tazobactam against members of Enterobacteriaceae.
Prakash SK; Arora V; Prashad R; Sharma VK
J Assoc Physicians India; 2005 Jul; 53():595-8. PubMed ID: 16190126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
